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PentosidineBazedoxifene (BZA) is used for the treatment of post-menopausal osteoporosis. To elucidate changes in collagen,
mineralization, and structural properties and their relationship to bone strength after treatment with BZA in
ovariectomized (OVX) monkeys, the levels of collagen and enzymatic immature, mature, and non-enzymatic
cross-links were simultaneously examined, as well as trabecular architecture and mineralization of vertebrae.
Adult female cynomolgus monkeys were divided into 4 groups (n = 18 each) as follows: Sham group, OVX
group, and OVX monkeys given either 0.2 or 0.5 mg/kg BZA for 18 months. Collagen concentration, enzymatic
and non-enzymatic pentosidine cross-links, whole ﬂuorescent advanced glycation end products (AGEs), trabec-
ular architecture, mineralization, and cancellous bone strength of vertebrae were analyzed. The levels of enzy-
matic immature and mature cross-links, bone volume (BV/TV), and trabecular thickness (Tb.Th) in BZA-
treated groupswere signiﬁcantly higher than those in theOVX control group. In contrast, the trabecular bone pat-
tern factor (TBPf), the structure model index (SMI), the enzymatic cross-link ratio, and the levels of pentosidine
and whole AGEs in BZA-treated groups were signiﬁcantly lower than those in the OVX control group. Stepwise
logistic regression analysis revealed that BV/TV, Tb.Th, TbPf, and pentosidine or whole AGEs independently af-
fected ultimate load (model R2=0.748, p b 0.001) and breaking energy (model R2=0.702). Stiffnesswas affect-
ed by Tb.Th, enzymatic immature cross-link levels and their ratio (model R2 = 0.400). Treatment with BZA
prevented OVX-induced deterioration in the total levels of immature enzymatic cross-links and AGEs accumula-
tion and structural properties such as BV/TV, Tb.Th, and TbPf, which contribute signiﬁcantly to vertebral cancel-
lous bone strength.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Bazedoxifene (BZA) is a novel indole-based third-generation selec-
tive estrogen receptor modulator (SERM) with unique structural char-
acteristics compared with other SERMs (e.g. raloxifene and tamoxifen)
[1,2]. BZA decreased the vertebral fracture risk in osteoporosis with a
smaller increase in bone mineral density (BMD) [3,4,5]. Because BMD
and bone qualities are important determinants of bone strength [6],h grants and/or consulting or
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. This is an open access article underBZA may show favorable effects on bone quality such as collagen
cross-link formation, mineralization, and microarchitecture. However,
little is known about the effects of BZA on bone quality and the degree
to which changes in bone qualitative properties induced by BZA treat-
ment contribute to bone strength.
The determinants of bonematerial properties are, among others, the
degree of mineralization, the collagen concentration, and the amount of
collagen cross-linking, including enzymatic divalent immature, triva-
lent mature, and non-enzymatic senescent types of cross-linking such
as advanced glycation end products (AGEs). Furthermore, the relative
ratio of hydroxylysine to lysine-derived enzymatic cross-links, as well
as the levels of cross-links, independently affects bone strength via the
regulation of collagen ﬁbrillogenesis [7–13].
Stabilization of newly formed collagen ﬁbers is initially achieved by
the formation of covalent cross-links between neighboring collagenthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
574 M. Saito et al. / Bone 81 (2015) 573–580molecules. Collagen cross-links can be divided into lysyl oxidase and ly-
sine hydroxylase mediated enzymatic cross-links and glycation- or
oxidation-induced non-enzymatic cross-links, AGEs. Enzymatic cross-
links are ﬁrst formed as divalent immature cross-links such as
dihydroxylysinonorleucine (DHLNL), hydroxylysinonorleucine (HLNL),
and lysinonorleucine (LNL) between the non-helical domains and the
helical domain of adjacent collagenmolecules [7–13]. A portion of diva-
lent immature cross-links spontaneously react to form trivalent mature
cross-links such as pyridinoline, deoxypyridinoline, pyrrole, and deoxy-
pyrrole. Enzymatic cross-link formation has positive effects on bone
mechanical properties within a beneﬁcial range without brittleness
[11–16]. In contrast, AGE cross-links lead to a ‘stiffer’ (not brittle) colla-
gen network, which leads to alterations in microdamage formation and
morphology and increased bone fragility [14,15,18–23]. AGE cross-links
are formed by oxidation or glycation reactions in a time-dependent
manner, which is regulated by tissue turnover rate [20], the degree
of oxidative stress [19,23,24], or glycation level [15,17,18,23,24].
Pentosidine is a well-established intermolecular cross-linking AGE [8,
9,12–15,17–20,23–25] and is used as a surrogate marker of whole
AGEs [8,9,23,26]. In this study, we determined the levels of pentosidine
and total ﬂuorescent AGEs (tfAGEs).
The purpose of this study was to clarify the long-term effect of BZA
treatment on trabecular structural properties, degree of mineralization,
and the levels of collagen enzymatic immature and mature cross-links,
pentosidine, and total AGEs in OVXmonkeys. The signiﬁcant contribut-
ing factors to vertebral cancellous bone strength after treatment with
BZA were analyzed.2. Materials and methods
2.1. Animals and experimental design
All animal procedures were as previously reported by Smith SY et al.
[27]. In this study, we used and evaluated bone strength, bone material,
and structural properties of the 12th thoracic vertebra (Th12) in the
previously reported bone turnover and BMD study [27]. The original
study [27] was sponsored by Wyeth Research, which was acquired by
Pﬁzer Inc. in October, 2009. The local afﬁliate, Pﬁzer Japan Inc., provided
frozen bones (T12) as well as funding for micro-CT analysis in the cur-
rent study.
Brieﬂy, skeletally mature female colony-bred cynomolgus monkeys
of Chinese origin (The Research Center of Primate Laboratory Animals,
Guangxi Forestry Province, Nanning, Guangxi, China), between 10 and
13 years of age andweighing 2.6–5.8 kg,were socially housed, generally
in pairs, with environmental conditions targeted at 24 °C (±3 °C), 50%
(±20%) relative humidity, and under controlled 12 h light/dark cycles
each day. Approximately 100 g of standard certiﬁed pelleted commer-
cial primate food (PMI Certiﬁed Laboratory Fiber-Plus® Monkey Diet
Jumbo 5050; PMI Nutrition International, St. Louis, MO, USA) was pro-
vided twice daily to animals in each housing unit, as well as daily fruit
and fruit-ﬂavored cookies (PrimaTreats, Bio-Serv, Frenchtown, NJ,
USA). Municipal tap water that had been softened, puriﬁed by reverse
osmosis, and sterilized by ultraviolet light was provided ad libitum.
This studywas conducted in compliancewith theGood Laboratory Prac-
tice Regulations and with US and Canadian Council on Animal Care
(CCAC) regulations for animal care and use.
Animals were acclimated for at least 6 weeks at the study site prior
to a 2-month baselinemonitoring period. Themonkeys underwent sur-
gical procedures (sham or OVX surgery) at the end of the baselinemon-
itoring period. For animals randomly assigned to undergo OVX, both
ovaries and surrounding tissues were excised completely. Animals in
the sham vehicle control group underwent a sham surgical procedure
in which their ovaries were extruded, but remained intact. Daily treat-
mentwith study drug or vehicle started the day following the sham op-
eration or OVX and continued for 18 months.In the original study, OVX monkeys receiving the study drug were
randomly assigned into ﬁve groups (n = 18 each) and each group
was treated with 0.2, 0.5, 1.0, 5.0 or 25.0 mg/kg/day of BZA (Wyeth Re-
search, Collegeville, PA, USA) by oral gavage for 18months [27]. We se-
lected the lowest two doses for the current study since they affect bone
strength and qualities. Unanesthetized animals were hand-restrained
during oral gavage. To acclimate the animals to the daily gavage proce-
dure, approximately 2 weeks before starting treatment all animals re-
ceived daily oral gavage of deionized water (5 mL/kg) using a rubber
catheter attached to a plastic syringe. During active treatment, the
daily dose was delivered using the same oral gavage technique in a
1–5 mL/kg suspension at approximately the same time each day. Two
additional groups of 18 animals (one sham-operated and one OVX)
served as controls and these received a 5 mL/kg solution of vehicle.
BZA was diluted with vehicle [1.0% polysorbate 80, NF; 0.5% methylcel-
lulose (4000 cps)] in deionized water and the pH was adjusted to
2.9–3.1 with 1.0 N acetic acid as needed.
All experiments were approved by the Experimental Animal Ethics
Committee at our institution and were conducted in accordance with
guidelines concerning the management and handling of experimental
animals.2.2. Preparation of bone
Following necropsy, the isolated Th12 vertebraewere cleaned of ad-
herent soft tissue, wrapped in saline-soaked gauze, and kept in a sealed
plastic bag. The samples were kept at−20 °C prior to testing.2.3. Micro-computed tomography measurements of bone trabecular
architecture
Cone-beam X-ray micro-computed tomography (micro-CT; MCT-
CB100MF, Hitachi Medico Technology, Kashima, Japan) was used to
take tomography images of the Th12 vertebral bodies with the follow-
ing settings: tube voltage, 55 kV; tube current, 0. mA; slice thickness
of 32 μm; and pixel size of 32 μm2. The specimens were located in the
axial direction and cross-sectional images (140 slices, approximately
4.5 mm high) were taken at the central portion of each Th12 vertebral
body. Three-dimensional images were reconstructed from these tomo-
grams and analyzed three-dimensionally using TRI/3D-BON software
(RATOC System Engineering, Tokyo, Japan). The following parameters
were obtained: cancellous bone volume (BV/TV, %), trabecular thickness
(Tb.Th, μm), trabecular number (Tb.N, 1/mm), trabecular separation
(Tb.Sp, μm), trabecular bone pattern factor (TBPf, 1/mm), and structure
model index (SMI) [28].2.4. Mechanical properties of vertebral cancellous bone
The cranial and caudal end plates of the Th12 vertebra were re-
moved with a bone saw (Labocutter MC-120, Maruto, Tokyo, Japan) to
obtain a vertebral body specimen with two parallel surfaces. The speci-
mens were placed on a lower platen with the cranial side facing up and
the cancellous region of each specimen was compressed with an upper
reduced-platen, 4 mm in diameter, using a material testing machine
(MZ-500S, Maruto, Tokyo, Japan) at a constant speed of 10 mm/min
over a displacement of 3 mm. Because the diameter of the platen is
4 mm, the platen compressed the area of cancellous bone [13] (Fig. 1).
The size of the reduced-platenwas determined using cross-sectional
images obtained bymicro-CTwith the diameter as large as possible, but
well within the endocortical perimeter. The load and displacement
curves were recorded and the following extrinsic parameters were
calculated by the testing machine software (CTRwin, System Supply,
Nagano, Japan): ultimate load (N), stiffness (N/mm), and breaking
energy (mJ).
Fig. 1. Compression test of vertebral cancellous bone.
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After mechanical testing, crushed cancellous bone was obtained
from the Th12 vertebral body. The cancellous bone samples were
cleaned of bonemarrow, frozen in liquid nitrogen, and pulverized in liq-
uid nitrogen as previously reported [13,22,29]. Measurement of cross-
links was carried out as previously described [29]. Brieﬂy, bone powder
was demineralized with 0.5 M EDTA in 50 mM Tris buffer (pH 7.4) for
96 h at 4 °C. Demineralized bone residues were suspended in potassium
phosphate buffer (pH 7.6) and reduced at 37 °C with sodium borohy-
dride (NaBH4; Sigma-Aldrich, St. Louis, MO, USA). The specimens were
hydrolyzed in 6 N HCl at 110 °C for 24 h. Hydrolysates were analyzed
for cross-links and hydroxyproline levels on a Shimadzu LC9 HPLC ﬁtted
with a cation exchange column (0.9 × 10 cm, Aa pack-Na; JASCO, Ltd.,
Tokyo, Japan). It was assumed that collagenweighed 7.5× themeasured
weight of hydroxyproline, with a molecular weight of 300,000 Da [29].
The resulting data were used to calculate cross-link values as mol/mol
of collagen. We determined the levels of enzymatic immature reducible
and mature non-reducible pyridinium cross-links such as pyridinoline
(Pyr), deoxypyridinoline (Dpyr), and AGE cross-linking (pentosidine).
Reducible immature cross-links (deH-DHLNL, deH-HLNL, and deH-LNL)
were identiﬁed and quantiﬁed according to their reduced forms
(DHLNL, HLNL, and LNL, respectively). Immature cross-links and hy-
droxyproline were detected with O-phthalaldehyde derivatization,
whereas Pyr, Dpyr, and pentosidine were detected by natural ﬂuores-
cence. Our established HPLC system enabled us to determine enzymatic
and non-enzymatic cross-link concentration within a linear range from
0.2 to 600 pmol in bone specimens. Because the degree of lysine hydrox-
ylation, which is a precursor of enzymatic cross-links, affects not only the
cross-link pattern, but also the biological characteristics of collagen such
as the mineralization process and ﬁbrillogenesis [10], the ratio of high to
low hydroxylated cross-links was estimated as (DHLNL+HLNL)/LNL or
Pyr/Dpyr [10,12,13]. The levels of tfAGEs were determined by the meth-
od of Tang et al. [30] and Ural et al. [31]. Brieﬂy, AGEs levels were deter-
mined using a ﬂuorescence reader (JASCO FP6200) at wavelengths of
370 nmexcitation and 440nmemission andnormalized to a quinine sul-
fate standard. Pentosidine is a useful surrogate marker of all ﬂuorescent
types of crosslinking AGEs in bone. Karim et al. [26] reported a signiﬁcant
relationship between pentosidine concentration and the bulk ﬂuores-
cence used to detect all AGEs by immunohistochemistry. We also
showed a similar relationship between the concentration of totalﬂuores-
cent AGEs and pentosidine in primate vertebral bone [23]. Crosslinking
AGEs such as pentosidine, crossline, and pyrropyridine, have natural
ﬂuorescence, whereas non-crosslinking AGEs do not ﬂuoresce except
GA pyridine. Because there are no reports regarding the existence of
GA pyridine in bone, determining the concentration of total ﬂuorescent
AGEs is suitable for estimating accumulation of crosslinking AGEs.2.6. Calcium and phosphorus concentration in cancellous bone
The bone powder of cancellous bone samples was dried in a drying
oven at 105 °C for 3 h, and weighed as dry weight. Bone powder was
pre-heated at 300 °C for 5 min using an electric heater, heated at 600 °C
for 5 h in an electric furnace, and weighed as ash weight. Each ashed
bone powderwas dissolved in 15ml of 30% (vol/vol) nitric acid solution
and heated at 80 °C for 20 min. 500 μL of Yttrium (1000 ppm) was
added as an internal standard. Calcium and phosphorus concentrations
of the bone solutions were measured using an ICP atomic emission
spectrometer (ULTIMA-2, Horiba, Tokyo, Japan) [13,25]. The amounts
of calcium and phosphorus were expressed as a percent of bone dry
weight.
2.7. Statistical analysis
All values are listed as mean ± standard deviation (SD). All groups
were compared to each other to conﬁrm statistical signiﬁcance by
ANOVAwith a Tukey–Kramer post-hoc test. A Spearman's rank correla-
tion coefﬁcient test was used to compare bone mechanical strength in
the OVX and BZA-treated groups with the following variables: bone
mass, trabecular architecture, mineral concentration, collagen levels,
collagen cross-links, and tfAGEs. Stepwise multiple regression analysis
was performed to predict bone strength from the various parameters.
All p-values less than 0.05 were considered signiﬁcant. All analyses
were performed using JMP software, Version 10 (JMP Institute Inc.,
Cary, NC, USA).
3. Results
3.1. Degree of mineralization
Regarding the degree ofmineralization, the concentration of calcium
(−3.3%, p = 0.010) and phosphorus (−3.1%, p = 0.017) in the OVX
group was signiﬁcantly lower than that of the SHAM group. There was
no signiﬁcant difference between the OVX and BZA groups (Table 1).
3.2. Trabecular architecture
The parameters of trabecular architecture in the OVX group signiﬁ-
cantly differed from those in the SHAM group (Table 1). The BV/TV
(−14%, p = 0.004) and Tb.Th (−11%, p = 0.003) were signiﬁcantly
lower than those in the SHAM group. In contrast, Tb.Sp (21%, p =
0.002), TBPf (p b 0.001), and SMI (45%, p b 0.001) were signiﬁcantly
higher than those in the SHAM group (Table 1).
The 0.2 (BZA0.2) and 0.5 (BZA0.5) mg/kg/day BZA groups showed
higher BV/TV (14%, p = 0.040 and 15%, p = 0.039), Tb.Th (10%, p =
0.024 and 6%, p = 0.332) and lower Tb.Sp (14%, p = 0.030 and 18%,
p = 0.006), TbPf (p = 0.002 and p = 0.003), and SMI (−30%, p =
0.002 and 32%, p = 0.002) than the OVX group (Table 1). There was
no signiﬁcant difference in Tb.Th between the OVX and the BZA0.5
groups. Tb.N was not signiﬁcantly different among the groups.
3.3. Collagen concentration and cross-links in cancellous bone
OVX signiﬁcantly lowered the concentration of collagen (−7%, p =
0.011) and total immature and mature cross-links, and the sum of im-
mature and mature cross-links (−15%, p b 0.001; −18%, p = 0.002;
and 15%, p b 0.001, respectively).
Conversely, the ratio of (DHLNL+HLNL)/LNL (200%, p b 0.001), the
ratio of Pyr/Dpyr (175%, p b 0.001), pentosidine (155%, p b 0.001), and
tfAGEs (116%, p = 0.011) were signiﬁcantly higher in the OVX group
than in the SHAMgroup (Table 1, Fig. 2). Therewas no signiﬁcant differ-
ence in the ratio of mature to immature cross-links between the SHAM
and the OVX groups (Table 1, Fig. 2).
Table 1
Comparison of collagen content, collagen cross-links, mineral content, and micro-CT among the experimental groups.
SHAM (n = 18) OVX (n = 18) BZA0.2 (n = 18) BZA0.5 (n = 18)
Ultimate load (N) 389.4 ± 86.5 350.9 ± 86.5 421.2 ± 121.6b 434.5 ± 62.8b
Stiffness (N/mm) 203.0 ± 54.3 204.6 ± 42.1 272.1 ± 63.0a,b 264.5 ± 60.8a,b
Breaking energy 761.2 ± 185.8 687.6 ± 122.1 887.7 ± 291.7b 907.0 ± 115.5b
Collagen content (% of tissue weight) 21.1 ± 1.9 19.6 ± 1.9a 21.4 ± 1.8b 21.2 ± 1.4b
Immature cross-links (mol/mol of collagen) 0.908 ± 0.082 0.774 ± 0.080a 1.061 ± 0.123b 1.074 ± 0.163b
Mature pyridinium cross-links (mol/mol of collagen) 0.145 ± 0.023 0.118 ± 0.024a 0.155 ± 0.020b 0.146 ± 0.030b
Immature + Mature pyridinium cross-links (mol/mol of collagen) 1.053 ± 0.091 0.891 ± 0.086a 1.216 ± 0.130b 1.221 ± 0.150b
Mature/Immature cross-links 0.160 ± 0.026 0.153 ± 0.035 0.139 ± 0.028 0.175 ± 0.043
Pentosidine (mmol/mol of collagen) 1.141 ± 0.201 1.763 ± 0.490a 0.768 ± 0.329b 0.856 ± 0.298b
Total ﬂuorescent AGEs (ng quinine/mg of collagen) 144.8 ± 28.1 168.1 ± 35.4a 117.0 ± 15.7a,b 120.7 ± 23.3b
(DHLNL + HLNL)/LNL 51.4 ± 4.6 102.8 ± 26.6a 59.8 ± 7.6b 56.1 ± 15.3b
Pyr/Dpyr 4.10 ± 0.77 7.61 ± 4.20a 3.70 ± 0.55a,b 3.65 ± 0.62a,b
Calcium content (mg/g of tissue dry weight) 233.5 ± 7.6 225.9 ± 8.2a 226.8 ± 8.0a 226.6 ± 10.2a
Phosphorus content (mg/g of tissue dry weight) 103.5 ± 3.4 100.3 ± 4.0a 101.3 ± 3.2a 100.2 ± 4.7a
BV/TV (%) 34.5 ± 4.8 29.5 ± 5.2a 33.6 ± 5.6b 33.8 ± 4.1b
Trabecular thickness (Tb.Th: μm) 145.1 ± 19.5 129.9 ± 12.6a 143.5 ± 11.6b 137.6 ± 9.8b
Trabecular number (Tb.N: 1/mm) 2.35 ± 0.34 2.20 ± 0.32 2.35 ± 0.35 2.42 ± 0.28
Trabecular separation (Tb.Sp: μm) 271.4 ± 39.0 328.6 ± 65.4a 281.3 ± 59.4b 269.4 ± 37.6b
Trabecular bone pattern factor (TbPf: 1/mm) −0.202 ± 0.747 1.003 ± 0.851a 0.009 ± 0.904a,b 0.023 ± 0.723a,b
Structure model index (SMI) 0.762 ± 0.281 1.102 ± 0.273a 0.771 ± 0.301b 0.752 ± 0.213b
Values are expressed as mean ± standard deviation (SD).
Immature cross-links: the sum of DHLNL, HLNL, and LNL.
Mature pyridinium cross-links: the sum of Pyr and Dpyr.
a p b 0.05 vs. SHAM.
b p b 0.05 vs. OVX.
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cross-link proﬁle to similar levels as the SHAM group (Table 1). The ac-
tual levels of enzymatic immature and mature pyridinium cross-links
was signiﬁcantly higher in the BZA0.2 group (immature cross-links:
37%, p b 0.001; mature cross-links: 31%, p b 0.001) and the BZA0.5
group (immature cross-links: 39%, p b 0.001; mature cross-links: 24%,
p b 0.001) than in the OVX group (Table 1, Fig. 2). There was no differ-
ence in the ratio ofmature pyridinium to immature cross-links between
OVX- and BZA-treated groups (Table 1). The deterioration of the high to
low hydroxylated lysine-derived enzymatic cross-link ratio, such as
DHLNL + HLNL/LNL and Pyr/Dpyr, was prevented in the BZA0.2
(−42%, p b 0.001 and −51%, p b 0.001, respectively) and BZA0.5
(−45%, p b 0.001 and−52, p b 0.001, respectively) groups and the ra-
tios were at the same level as the SHAM group (Table 1, Fig. 2).
Pentosidine and tfAGEs levels were signiﬁcantly lower in the BZA0.2
(−56%, p b 0.001 and −30%, p b 0.001, respectively) and BZA0.5
(−51%, p b 0.001 and −28%, p b 0.001, respectively) groups than in
the OVX group (Table 1, Fig. 2).Fig. 2. Effect of BZA at two doses on the concentration of collagen cross-links in vertebral bone. (
cross-link: pentosidine. (c) Totalﬂuorescent AGEs. Values are themean± SD. ap b 0.05: vs. SHA3.4. Contributors to the improvement of cancellous bone strength by BZA
treatment.
The mean values of ultimate load and breaking energy in the OVX
groupwere lower than those in the SHAM group, although these differ-
ences did not reach statistical signiﬁcance (Table 1 and Fig. 3). These pa-
rameters of bone strength were higher in the BZA0.2 (ultimate load:
20%, p = 0.066, stiffness: 33%, p = 0.003, breaking energy: 29%, p =
0.014) and BZA0.5 groups (ultimate load: 24%, p = 0.031, stiffness:
29%, p = 0.013, breaking energy: 32%, p b 0.001) than in the OVX
group (Fig. 3). Stiffness was signiﬁcantly higher in the BZA0.2 (34%,
p = 0.006) and BZA0.5 (30%, p = 0.019) groups than in the SHAM
group (Table 1, Fig. 3).
BV/TV, Tb.Th, and immature cross-links were signiﬁcantly and posi-
tively correlated with ultimate load, stiffness, and breaking energy by
Spearman's rank correlation analysis (Table 2). The mature pyridinium
cross-links and total enzymatic cross-links estimated by the sum of im-
mature andmature cross-links showed a signiﬁcant positive correlationa) Enzymatic cross-links: the sumof DHLNL, HLNL, LNL, Pyr, and Dpyr. (b) Non-enzymatic
M. bp b 0.05: vs. OVX. BZA0.2 and BZA0.5means 0.2 and 0.5mg/kg/day of BZA, respectively.
Fig. 3.Effect of BZA at two doses on Th12 vertebral cancellous bone strength. (A)Ultimate load; (B) Stiffness; (C) Breaking energy. Values are themean±SD. ap b 0.05: vs. SHAM. bp b 0.05:
vs. OVX. BZA0.2 and BZA0.5 means 0.2 and 0.5 mg/kg/day of BZA, respectively.
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the ratio of (DHLNL + HLNL)/LNL, and Pyr/Dpyr showed a signiﬁcant
negative correlation to bone strength (Table 2). There was no correla-
tion between bone strength and the concentration of collagen, calcium,
and phosphorus.
We performed stepwise multiple regression to reveal associations
between bone strength and their determinants such as material and
structural parameters (Table 3). BV/TV, Tb.Th, TbPf, and the levels of
pentosidine associated signiﬁcantly and independently with ultimate
load (model R2 = 0.785). Breaking energy (model R2 = 0.702) was ex-
plained by BV/TV, Tb.Th, TbPf, the levels of tfAGEs, and the ratio of
(DHLNL + HLNL)/LNL. The levels of enzymatic immature cross-links
and the ratio of (DHLNL + HLNL)/LNL were signiﬁcant determinants
of stiffness that were independent of Tb.Th (model R2 = 0.400).
4. Discussion
This study demonstrated that BZA treatment reversed the deleteri-
ous changes in collagen concentration, the non-enzymatic AGEs cross-Table 2
Spearman rank correlation coefﬁcient (r) between theparameters of bonemass, structural
and material determinants and bone biomechanical properties.
Stiffness
Breaking
energy
Ultimate
load
r r r
Collagen content 0.138 0.100 0.096
Immature cross-links 0.475b 0.314a 0.211a
Mature pyridinium cross-links 0.553a 0.077 0.034
Immature + Mature pyridinium cross-links 0.343a 0.112 0.009
Mature/Immature cross-links 0.131 0.023 0.066
Pentosidine −0.337a −0.373b −0.356a
Total ﬂuorescent AGEs −0.292a −0.229a −0.220a
(DHLNL + HLNL)/LNL −0.353a −0.386b −0.310a
Pyr/Dpyr −0.313a −0.202 −0.191
Calcium content −0.136 0.032 0.062
BV/TV 0.425b 0.725c 0.829c
Tb.Th 0.353a 0.615c 0.670c
Tb.N 0.252 0.434b 0.520c
Tb.Sp −0.417b −0.571c −0.640c
SMI −0.283a −0.592c −0.691c
TbPf −0.306a −0.683c −0.794c
Immature cross-links: the sum of DHLNL, HLNL, and LNL.
Mature pyridinium cross-links: the sum of Pyr and Dpyr.
a p b 0.05.
b p b 0.01.
c p b 0.001.link pentosidine, enzymatic immature and mature cross-links, and tra-
becular architecture in OVX monkeys.
4.1. Trabecular architecture following BZA treatment
OVX monkeys are commonly used as a non-human primate model
of post-menopausal osteoporosis [13,23,27]. In this study, we evaluated
Th12 vertebrae from a previously reported bone turnover and BMD
study [27]. Smith et al. [27] demonstrated that OVX resulted in signiﬁ-
cant increases in biochemical markers such as bone-speciﬁc alkaline
phosphatase (BAP), osteocalcin (OC), C-telopeptide (CTx), and urinary
N-telopeptide (NTx) as well as cancellous bone formation and resorp-
tion as evaluated by dynamic histomorphometric evaluation of long
bone diaphyses and femoral neck cancellous bone. Based on data from
bone of the same monkey [27], BZA treatment partially suppressed
the OVX-induced 2- to 3-fold increase in bone turnover markers, al-
though BZA had no signiﬁcant effect on OVX-induced changes in static
or dynamic histomorphometric parameters in femoral neck trabecular
bone. There is no information regarding the histomorphometric param-
eters in vertebral cancellous bone in OVXmonkeys. The plausible expla-
nation of preservation of trabecular parameters to similar levels as the
sham group may be due to suppression of bone turnover although the
actual histomorphometric data of vertebral cancellous bone is needed
in the future study (Table 1). In terms of degree of mineralization, a fur-
ther histomorphometric analysis is needed in same bone.Table 3
Predictionmodels ofmechanical bone strength by structural andmaterial properties using
stepwise regression analysis.
β p value Model r2
Ultimate load
BV/TV 362.7 b0.001 0.785
Tb.N −126.5 b0.001
TbPf 98.8 0.071
Pentosidine −26.1 0.040
Stiffness
Tb.Th 43.2 0.014 0.400
Immature cross-links 33.5 0.050
(DHLNL + HLNL)/LNL −55.5 0.004
Breaking energy
BV/TV 946.1 b0.001 0.702
Tb.N −377.2 b0.001
TbPf 332.9 0.035
Total ﬂuorescent AGEs −62.3 0.080
(DHLNL + HLNL)/LNL −174.5 0.009
The results of the structural and material properties are shown in Table 1.
Immature cross-links: the sum of the actual amount of DHLNL, HLNL, and LNL.
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It is unknown whether the OVX monkeys show a similar deteriora-
tion to human post-menopausal osteoporosis regarding the actual
levels of immature divalent and mature trivalent enzymatic cross-
links and AGEs cross-linking. We showed that the OVX group exhibited
collagen abnormalities similar to those reported in our bone biopsy data
from post-menopausal hip fracture cases and OVX rats (Table 1, Fig. 2)
[7,8,12,17,25,33,34]. These results are consistentwith our previously re-
ported OVXmonkeys [13,23]. Ozasa et al. [35] demonstrated inOVX rats
that the activity of lysyl oxidase-catalyzed enzymatic cross-link forma-
tion decreased by 25% three days after OVX, but activity was completely
rescued by estradiol injection. This indicates that estrogenmay be a reg-
ulatory factor for enzymatic cross-link formation. In this study, estrogen
deﬁciency induced by OVX resulted in a decrease of the total amount of
enzymatic cross-link formation. Ireland et al. [36] showed that estrogen
stimulates type I collagen synthesis via the induction of estrogen recep-
tors and accelerates mineralization in vitro using human bone-derived
osteoblasts. The other candidate of impaired enzymatic cross-link for-
mation by estrogen deﬁciency is oxidative stress. It is well known that
post-menopausal decreases in estrogen increase oxidative stress as
well as age-dependent renal dysfunction [36–38]. It is thought that ox-
idative stress reduces lysyl oxidase activity [39,40]. We showed that in-
creased oxidative stress decreases enzymatic cross-link formation in
bone from mice deﬁcient in cytoplasmic copper/zinc superoxide dis-
mutase (CuZn-SOD, encoded by the Sod1gene; Sod1−/−)[24]. Because
this resultwas evidentwithout OVX in the knockoutmice, increased ox-
idative stress may deteriorate enzymatic cross-linking in bone. These
results indicate that impaired enzymatic cross-links in the OVX group
might be attributed to estrogen deﬁciency via the interaction with the
estrogen receptor and increased oxidative stress. In this study, there
was a signiﬁcant negative correlation between the concentrations of en-
zymatic crosslinks and tfAGEs (R2 = 0.313, p b 0.0001). AGEs are
thought to be formed by lysine residues, which are essential sites of en-
zymatic cross-linking in collagen, and result in competitively inhibiting
formation of enzymatic cross-links [7,33]. Therefore, the other candi-
date for impaired enzymatic cross-link formation may be excessive
AGEs formation.
In terms of AGEs accumulation in bone, formation of AGEs occurs
in a time-dependent manner in physiological conditions. However,
AGEs formation is markedly increased during excessively elevated ox-
idative stress, even when bone turnover rates and glycemic control
are within normal or high ranges [8,19,41]. We demonstrated that
cortical [12] and cancellous [22] bone from patients with primary os-
teoporosis without diabetes or renal failure, but with a high turnover
rate as estimated by urinary DPD levels, contained signiﬁcantly higher
pentosidine levels in both low and high mineralized bone tissue.
Therefore, the signiﬁcant increased accumulation of pentosidine and
tfAGEs in the OVX group may be due to oxidative stress induced by
estrogen deﬁciency.
Ozasa et al. [35] and Sanada et al. [42] demonstrated in a rodent
model that reduced lysyl oxidase activity induced by OVX was
completely improved by estradiol injection. Khastgir et al. [43] showed
that estrogen hormone replacement therapy (HRT) increased enzymat-
ic cross-links in bone from elderly post-menopausal women with oste-
oporosis. Paschalis et al. [44] also demonstrated the beneﬁcial effects of
HRT and RLX on enzymatic cross-link ratios assessed by FTIRI when
paired biopsy specimens were compared before and after 2 years of
HRT. These resultswere consistentwith our previous study,whichdem-
onstrated the favorable effects of raloxifene (RLX), a second generation
SERM, on collagen enzymatic and non-enzymatic AGEs cross-links in
OVX rabbits with or without hyperhomocysteinemia [19]. RLX in-
creased the concentration of enzymatic cross-links, while decreasing
AGEs cross-links after 16 weeks of treatment. The relatively short treat-
ment duration is only 16 weeks in this report suggests that the marked
increase in crosslink concentration cannot be explained by remodelingalone. Not all enzymatic crosslink precursors, such as Lys and Hyl resi-
dues in collagen molecules, are cross-linked. Therefore, if lysyl oxidase
activity is increased by estrogen or SERMs, the Lys andHylmay form ad-
ditional crosslinks in preexisting collagenﬁbers independent of bone re-
modeling. Gallant et al. [45] reported that ex vivo exposure of nonviable
bone to raloxifene improves intrinsic toughness. These effects are cell
independent and appear to be mediated by an increase in matrix-
bound water. The hydroxyl groups (OH) on raloxifene were shown to
be important for the increase of bothwater content and toughness. Sim-
ilar results were reported by Allen et al. [46] using ultra-short echotime
magnetic resonance imaging (UTE-MRI) in vivo. These results lead us to
believe that there is also a change in matrix-bound water and an in-
crease in the crosslinks of preexisting collagen. In this study,we demon-
strated that a clinical dose of BZA for 18 months prevented the OVX-
induced deleterious changes in immature and mature pyridinium
cross-links and excessive hydroxylation of cross-links, pentosidine,
and tfAGEs. Such changes in cross-link formation signiﬁcantly contrib-
uted to the preservation of bone strength (Tables 2 and 3). BZA is well
known to act as an estrogen agonist in bone via the binding to the estro-
gen receptor in bone cells and this interaction reduces oxidative stress
[1,47]. Such positive effects of HRT and RLX on collagen cross-links
may provide a possible explanation for the prevention of OVX-
induced deterioration of collagen crosslink formation such as the
amount of enzymatic cross-links, pentosidine and tfAGEs that was de-
tected in the BZA group.
Our study had several limitations. First, we focused on vertebral can-
cellous bone so we cannot deﬁnitively state whether the observed
changes in bone mass, quality, and strength are applicable to whole
bone strength including cortical bone. Second, we did not evaluate
other determinants of material properties such as matrix-bound water
and non-collagenous proteins, which may also affect bone strength.
Third, enzymatic mature pyrrole cross-links may be as important as
pyridiniumcross-links [7,33]. However, since pyrrole cross-links are un-
stable during acid hydrolysis, we could not measure them using our
HPLC method. Thus, we analyzed conventional immature divalent
cross-links, mature pyridinium cross-links, pentosidine, tfAGEs, and hy-
droxyproline analysis after acid hydrolysis. Since themajor determinant
of the total amount of immature divalent cross-links, which is the pre-
dominant type in bone collagen, and mature cross-links, such as
pyridinium and pyrrole, is lysyl oxidase activity, the overall formation
of pyrrole cross-links might be similar to other lysyl oxidase-
controlled cross-linking. There is no doubt that not only pyridinium
cross-links, but also pyrroles independently affect tissue strength [7,
33]. Indeed, human bone appears to contain pyrrole and pyridinium
cross-links to the same extent [7,33]. Third, glucosepane is the major
type of non-ﬂuorescent AGEs. Glucosepane accumulates in the human
extracellular matrix with aging in the skin and glomerular basement
membrane [48]. Biemel et al. [49] demonstrated the structural similari-
ties between pentosidine and glucosepane, which suggests a parallel
mechanism in the respective formation pathways. However, to date,
glucosepane in bone and changes in aging and estrogen deﬁciency
have not been reported. Thus, the presence of glucosepane in bone col-
lagen aswell as skin and basementmembrane should be conﬁrmed and
we should attempt to clarify the role of glucosepane in human and pri-
mate bone in future studies. Fourth, bone strength parameters were not
signiﬁcantly different between OVX and SHAM, in spite of the differ-
ences in micro-CT microarchitecture parameters. Although the mean
values of ultimate load and breaking energy in the OVX group were
lower than those in the SHAM group, these differences did not reach
statistical signiﬁcance. However, all parameters ofmicroarchitecture es-
timated by micro-CT correlated signiﬁcantly to ultimate load, stiffness,
and breaking energy in SHAM and OVX groups by Spearman's rank cor-
relation coefﬁcient analysis excluding the BZA-treated groups. Thus,
microarchitecture affects bone strength. In previous reports using OVX
monkeys, there was no signiﬁcant reduction in bone strength in spite
of the differences in microarchitecture and bone mineral density,
579M. Saito et al. / Bone 81 (2015) 573–580which may be due to individual differences [13,50–52]. Thus, this may
be a limitation of OVX monkeys.
In conclusion, the prevention of OVX-induced deterioration of the
actual amount of enzymatic immature andmature cross-link formation,
the ratio of hydroxylysine-derived enzymatic cross-links, the non-
enzymatic cross-link, pentosidine, and tfAGEs by BZA for 18 months in
cynomolgus monkeys coincided with preservation of vertebral cancel-
lous bone strength. The levels of enzymatic immature cross-links,
pentosidine, and whole ﬂuorescent AGEs after treatment with BZA sig-
niﬁcantly contributed to vertebral cancellous bone strength.Acknowledgments
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